ProSomnus, Inc.
OSAAW
NASDAQ Global Market0.02
USD
+0.00
- -
ProSomnus, Inc.
OSAAW
(NASDAQ Global Market)
Recent
price
0.02
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- ProSomnus, Inc. (NASDAQ:OSAAW) develops, manufactures and markets precision intraoral medical devices for the treatment of obstructive sleep apnea (OSA) and snoring as patient-preferred alternatives to CPAP therapy; its core products include the FDA-cleared EVO line of oral appliance therapy (OAT) devices such as EVO, EVO [PH], EVO Guided and [CA] LP, featuring advanced materials like MG6 technology, iterative advancement mechanisms, anterior openings, dual Optipost designs and customization options for optimal airway management, comfort and efficacy. Founded in 2016 and headquartered in Pleasanton, California, the company sells its devices to sleep dentists, physicians, otolaryngologists and integrated healthcare providers through a direct sales force, primarily targeting the U.S. market with plans for international expansion. In recent developments, ProSomnus secured $30 million in convertible note financing in late 2024 led by Cohanzick Management and CrossingBridge Advisors to support its merger with Lakeshore Acquisition I Corp., balance sheet strengthening and growth initiatives including sales team expansion and next-generation sensor-embedded devices; it launched the EVO Guided appliance in 2025, appointed Jason Orchard as CFO, obtained additional growth capital from Spring Mountain Capital, Littlejohn & Co. and Masters Special Situations, earned DPF certification and repeated as an Inc. 5000 honoree for fastest-growing companies.